![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/emalex-biosciences-announces-first-patient-dosed-in-phase-3-trial-of-ecopipam-for-tourette-syndrome-301759554.html
https://www.clinicaltrialsarena.com/news/emalex-biosciences-tourette-syndrome/
https://www.prnewswire.com/news-releases/emalex-biosciences-publishes-phase-2b-results-for-tourette-syndrome-candidate-in-pediatrics-301719240.html
https://www.fiercebiotech.com/biotech/tourette-focused-emalex-rakes-250m-series-d-funding-7x-larger-its-series-c
https://www.prnewswire.com/news-releases/emalex-biosciences-expands-cns-platform-to-advance-treatment-for-restless-legs-syndrome-with-augmentation-301492231.html
https://www.prnewswire.com/news-releases/emalex-biosciences-recruiting-people-who-stutter-for-phase-2-clinical-trial-for-childhood-onset-fluency-disorder-301375816.html
https://endpts.com/jeff-aronins-emalex-raises-35m-series-c-british-protein-degradation-biotech-emerges-from-stealth/